# Hemoglobin-Based Oxygen Carriers: Selected Advances and Challenges in the Design of Safe Oxygen Therapeutics (A Focused Review)

**Authors:** Waldemar Grzegorzewski, Anna Czerniecka-Kubicka, Katarzyna Gołda, Alicja Niedźwiedzka, Hanna Wollocko, Michał S. Majewski, Joanna Wojtkiewicz

PMC · DOI: 10.3390/ijms26199775 · 2025-10-08

## TL;DR

This review discusses the potential of hemoglobin-based oxygen carriers as blood substitutes and highlights recent advances and challenges in their development for clinical use.

## Contribution

The paper provides a focused review on recent design advances and challenges in hemoglobin-based oxygen carriers for safe oxygen therapeutics.

## Key findings

- HBOCs aim to mimic red blood cell oxygen transport while overcoming storage and compatibility issues.
- Despite decades of research, no HBOC has met all clinical criteria for widespread use.
- Current limitations include safety concerns and translational barriers to routine clinical adoption.

## Abstract

Blood transfusion is a routine yet resource-intensive medical procedure. Increasing global demand, limited donor availability, and logistical and ethical constraints have driven the search for adequate blood substitutes. Hemoglobin-based oxygen carriers (HBOCs) represent a promising class of therapeutics designed to mimic the oxygen transport function of red blood cells while overcoming the challenges of storage, compatibility, and infection risk. Despite decades of research, no HBOC has yet met all criteria for widespread clinical use. This review summarizes recent advances in the design and development of hemoglobin derivatives, with a focus on their biochemical properties, safety profiles, and oxygen delivery capabilities. We also discuss current limitations and translational barriers. The successful implementation of HBOCs could significantly improve transfusion strategies, especially in emergency medicine, military applications, and resource-limited settings. Continued innovation is essential to bring safe and effective oxygen therapeutics into routine clinical practice.

## Linked entities

- **Proteins:** HB1 (hemoglobin 1)

## Full-text entities

- **Diseases:** infection (MESH:D007239), HBOC (MESH:D061325)
- **Chemicals:** Oxygen (MESH:D010100)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12525027/full.md

---
Source: https://tomesphere.com/paper/PMC12525027